

When small becomes big: The new challenges of orphan drugs in Europe

Orphan drugs landscape quickly becoming a commercially attractive market

LONDON, UNITED KINGDOM, January 24, 2017 /EINPresswire.com/ -- Throughout the years the European pharmaceutical <u>landscape</u> has undergone a significant shift, resulting in an increasing acknowledgment of specialty medicines and diseases with lesser patient population.



The orphan drugs landscape has become a

commercially attractive market as a result of vigorous patient advocacy, medical breakthroughs, regulatory incentives and venture capital investment.

This year's 6th annual Orphan Drugs and <u>Rare Diseases</u> Europe conference will deliver an in-depth overview of the regulatory landscape, pricing strategy and orphan drug development over two days.

Bertram Haussler, Chairman of the Board of Management, IGES Institut will be presenting the host nation address, which will be focused on active measures to improve the health situation of those living with rare diseases in Germany.

Some of the topical areas of discussion will include regulatory developments, strategies for best route to market, pricing and reimbursement concerns including the controversial German pricing mechanism. Other conference highlights to expect this year will include:

- SIX spotlight sessions
- Opening keynote from Alexion Pharma
- Host nation address from IGES Institut
- TWO interactive post conference workshops
- Topical panel discussion from Global Market Access Solutions, Agerion Pharmaceuticals, RBV Capital
- FIVE+ hours of networking opportunities with senior industry professionals
- Global drug market case studies from Italy, Middle East, Greece & the UK

Visit <u>www.orphandrugs-event.com/ein</u> for more information or to view the complete two day agenda.

There is currently a £400 early bird discount for all bookings made before 31st January.

Orphan Drugs and Rare Diseases Europe 2017 15th – 16th May 2017 Berlin, Germany <u>www.orphandrugs-event.com/ein</u> Follow the conversation on Twitter and LinkedIn at #SMiOD17 Kyra Williams SMi Group Ltd +44 (0)20 7827 6012 email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2017 IPD Group, Inc. All Right Reserved.